Britton Zuccarelli
Neurology with Special Qualifications in Child Neurology · Salina, KSNPI 1679869002
Payments from drug & device makers
Across 457 payments — averaging $686.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$230K
- Neurelis, Inc.$60K
- Supernus Pharmaceuticals, Inc.$10K
- Livanova USA, Inc.$8K
- Novartis$3K
- Jazz Pharmaceuticals Inc.$1K
- plus $1K from 16 others
What the payments were for
- Consulting fees$33,90411%
- Speaking & faculty fees$233,21674%
- Travel & lodging$41,00513%
- Food & beverage$5,3152%
- Education$1820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 282 | $229,611 |
| Neurelis, Inc. | 97 | $60,050 |
| Supernus Pharmaceuticals, Inc. | 18 | $10,314 |
| Livanova USA, Inc. | 18 | $8,273 |
| Novartis | 4 | $2,965 |
| Jazz Pharmaceuticals Inc. | 10 | $1,304 |
| Ceribell, Inc. | 1 | $450 |
| AbbVie | 4 | $141 |
| Greenwich Biosciences, Inc. | 1 | $114 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $88 |
| Sanofi Pasteur Inc. | 5 | $84 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Corium, LLC | 3 | $32 |
| Pharming Healthcare, Inc. | 1 | $25 |
| GSK | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| Seqirus USA Inc | 1 | $15 |
| SK Life Science, Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPINRAZA$213,972
- VALTOCO$59,165
- QELBREE$7,100
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$6,600
- ZOLGENSMA$2,825
- VNS Therapy$1,366
- Epidiolex$1,088
- POCKET EEG DEVICE$450
- XYWAV$150
- XYREM$150
How this compares
Too few neurology with special qualifications in child neurology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| QalsodyTofersen | 12 | $177,683 |
| EpidiolexCannabidiol (Cbd) | 15 | $113,158 |
| FetzimaLevomilnacipran Hcl | 19 | $9,367 |
| Lisdexamfetamine Dimesylate | 15 | $5,201 |
| Clonazepam | 13 | $435 |
| Lamotrigine | 14 | $163 |
| Ropinirole Hcl | 13 | $155 |
| Sertraline Hcl | 12 | $128 |
| Topiramate | 19 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenQalsody | $229,611 | $177,68312 claims |
| AbbVieFetzima | $141 | $9,36719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology with special qualifications in child neurology providers in Kansason file to place this against a meaningful peer group, so we don't.
Other neurology with special qualifications in child neurology in Salina
- Jean-Baptiste le PichonTopeka$815K
- Yu Tze NgOverland Park$377K
- Bassem El-NabboutWichita$318K
- Gina JonesTopeka$177K
- Subhash ShahWichita$2K
- Aruna Deepthi Markonda PatnaikWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.